Sacituzumab tirumotecan has recently received marketing authorization in China by the National Medical Products Administration (NMPA) for the treatment of patients with EGFR-mutant advanced NSCLC following progression on TKI therapy and platinum-based chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.